Clinical trials: Cachexia
Malnutrition, Wasting
Nutritional Impact of Moringa Oleifera Leaf Supplementation in Mothers and Children
Studies to date on the effects of Moringa oleifera in diabetes and anemia and animal studies that examine the utility of moringa for increased milk and litter yield are of small scale, however high-quality large-scale placebo or…
- Conditions
- Malnutrition, Wasting, Growth Failure
- Trial name
- NCT04587271
- Testing
- Moringa oleifera (high dose), Moringa oleifera (low dose)
- Where
- 2 sites in Kenya
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Suzanna L Attia
Non-small Cell Lung Cancer, Cachexia
Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer.
The purpose of this study is to assess the frequency of cachexia and the management of cachexia and associated symptoms in a patient population with non-small cell lung cancer (NSCLC).
- Trial name
- CacheMire (NCT02968979)
- Where
- France
- Volunteers
- 539 people
- Sponsor
- Chugai Pharma France
Pulmonary Disease, Chronic Obstructive (COPD)
Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices
The purpose of this study was to compare dynamic inspiratory flow rates achieved by a population of Chronic Obstructive Pulmonary Disease (COPD) patients through the Breezhaler®, Ellipta® and Handihaler® dry powder inhaler (DPI)…
- Trial name
- NCT02596009
- Testing
- Breezhaler®, Ellipta®, Handihaler®
- Where
- 5 sites in Argentina
- Volunteers
- 97 people
- Sponsor
- Novartis Pharmaceuticals
ICU Acquired Weakness
Evaluation of FDY-5301 in Major Trauma Patients in ICU
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of FDY-5301 compared to placebo in major trauma ICU patients at risk of intensive care unit acquired weakness (ICUAW)
- Trial name
- NCT04430283
- Testing
- FDY-5301
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Type 2 Spinal Muscular Atrophy
Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)
This was a Phase III multi-center, single dose (1.2 x 10^14 vector genomes), randomized, sham controlled, double-blind study that investigates the efficacy, safety and tolerability of OAV101B in treatment naive, sitting and never…
- Trial name
- STEER (NCT05089656)
- Testing
- OAV101
- Where
- 42 sites in United States, Brazil and 11 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Anorexia, Weight Loss
Haelan and Nutrition in Cancer Patients
Primary: To determine if treatment with Haelan (fermented soy product) can decrease the severity of poor appetite measured using a visual analog scale (VAS) of 0 to 100 mm (0 mm = best, 100 mm = worst) at week 4 +/- 5 days.
- Conditions
- Anorexia, Weight Loss, Cachexia
- Trial name
- NCT00558558
- Testing
- Haelan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Anorexia, Cachexia
Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients
Purpose of the study is to compare the effects of megestrol acetate concentrated suspension and placebo on caloric intake for the treatment of cancer-associated anorexia in patients with lung or pancreatic cancer
- Conditions
- Anorexia, Cachexia, Weight Loss
- Trial name
- NCT00637728
- Testing
- Megestrol acetate concentrated suspension 110 mg/mL
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Par Pharmaceutical, Inc.
HIV Lipodystrophy
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
The purpose of this study is to determine whether patients with HIV lipodystrophy (fat wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either metformin or pioglitazone, both diabetes drugs) and…
- Trial name
- NCT00362440
- Testing
- Leptin, Pioglitazone or metformin
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life.
- Trial name
- NCT01388920
- Testing
- Tesamorelin
- Volunteers
- 3 people
- Sponsor
- Theratechnologies
Cancer Cachexia
A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia
The data collected through this pilot study will allow us to increase our understanding of cancer cachexia and the effect of Eicosapentaenoic Acid (EPA) on cancer cachexia.
- Trial name
- NCT00815685
- Testing
- Eicosapentaenoic Acid
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cystic Fibrosis
Growth Hormone Therapy for Wasting in Cystic Fibrosis
Our hypothesis is that Growth Hormone (GH) will not only target the peripheral tissue to stimulate weight and muscle growth which will maximize nutritional potential and improve overall quality of life.
- Trial name
- NCT00803179
- Testing
- Nutropin AQ
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Massachusetts, Worcester
Cachexia; Cancer, Non Small Cell Lung Cancer
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2
The goal of this clinical trial was to compare the efficacy and safety of anamorelin HCl (the investigational drug) to that of placebo (tablet with no drug) in patients with advanced non-small cell lung cancer and cachexia…
- Trial name
- NCT03743064
- Testing
- anamorelin HCl
- Where
- 65 sites in United States, Australia and 6 more
- Volunteers
- 318 people
- Sponsor
- Helsinn Healthcare SA
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo.
- Trial name
- NCT01669174
- Testing
- BYM338
- Where
- 9 sites in United States, Netherlands and 1 more
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Sarcopenia
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
- Trial name
- NCT02468674
- Testing
- bimagrumab
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Hypercatabolic Status Related to Severe Burn
Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects
Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks
- Trial name
- NCT02074995
- Testing
- BVS857
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Cachexia
Regimen for the Treatment of Cachexia in Subjects With NSCLC
Cachexia is a presentation of a chronic manifestation of acute metabolic stress, a hypercatabolic nutritional state in which the normal fat and protein sparing mechanisms are not functioning and increased nutrition is not…
- Trial name
- VT-122 (NCT00527319)
- Testing
- VT-122 low dose, VT-122 high dose
- Where
- 8 sites in United States, India
- Volunteers
- 37 people
- Sponsor
- Vicus Therapeutics
Muscular Atrophy, Spinal
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
This was a phase IV Open-label, single-arm, single-dose, multicenter study, to evaluate the safety, tolerability and efficacy of intravenous administration of OAV101 (AVXS-101) in patients with SMA with bi-allelic mutations in…
- Trial name
- OFELIA (NCT05073133)
- Testing
- OAV101
- Where
- 5 sites in Argentina, Brazil
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Cachexia, Non-Small Cell Lung Cancer
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01387269
- Testing
- Anamorelin HCl
- Where
- 60 sites in United States, Belarus and 14 more
- Volunteers
- 484 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Cachexia
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
- Trial name
- NCT01433263
- Testing
- BYM338 active drug
- Where
- 10 sites in United States, Lithuania and 3 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease
Intradialytic Progressive Resistance Training for Maintenance Haemodialysis Patients
The purpose of this study is to investigate the effects of a 12 week progressive resistance training during haemodialysis on muscle quantity and physical functioning in chronic kidney disease patients receiving maintenance…
- Trial name
- PRT (NCT01007838)
- Testing
- Progressive resistance training programme, Progressive resistance training
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Bangor University